NasdaqGS - Delayed Quote • USD
Biogen Inc. (BIIB)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:51 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 27 | 27 | 32 | 32 |
Avg. Estimate | 3.97 | 3.97 | 15.59 | 17.47 |
Low Estimate | 3.4 | 3.01 | 14.91 | 13.76 |
High Estimate | 6.04 | 4.29 | 16.37 | 21.11 |
Year Ago EPS | 4.02 | 4.36 | 14.72 | 15.59 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 26 | 25 | 32 | 32 |
Avg. Estimate | 2.37B | 2.4B | 9.49B | 9.54B |
Low Estimate | 2.32B | 2.25B | 8.98B | 8.59B |
High Estimate | 2.45B | 2.5B | 9.69B | 10.37B |
Year Ago Sales | 2.37B | 2.53B | 9.84B | 9.49B |
Sales Growth (year/est) | 0.40% | -5.20% | -3.50% | 0.50% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | 3.77 | 3.97 | 3.18 | 3.45 |
EPS Actual | 4.02 | 4.36 | 3.3 | 3.67 |
Difference | 0.25 | 0.39 | 0.12 | 0.22 |
Surprise % | 6.60% | 9.80% | 3.80% | 6.40% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 3.97 | 3.97 | 15.59 | 17.47 |
7 Days Ago | 3.94 | 3.98 | 15.44 | 17.43 |
30 Days Ago | 3.94 | 4 | 15.48 | 17.62 |
60 Days Ago | 3.95 | 4 | 15.49 | 17.64 |
90 Days Ago | 3.89 | 4.25 | 15.68 | 18.44 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 11 | 11 | 23 | 12 |
Up Last 30 Days | 13 | 12 | 23 | 12 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 13 | 15 | 5 | 15 |
Growth Estimates
CURRENCY IN USD | BIIB | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -1.20% | -- | -- | 5.40% |
Next Qtr. | -8.90% | -- | -- | 10.90% |
Current Year | 5.90% | -- | -- | 4.50% |
Next Year | 12.10% | -- | -- | 13.10% |
Next 5 Years (per annum) | 3.20% | -- | -- | 10.94% |
Past 5 Years (per annum) | -18.85% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Maintains | Barclays: Equal-Weight to Equal-Weight | 4/25/2024 |
Maintains | Wedbush: Neutral to Neutral | 4/25/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
Reiterates | Needham: Buy to Buy | 4/25/2024 |
Reiterates | Needham: Buy to Buy | 4/24/2024 |
Maintains | Oppenheimer: Outperform to Outperform | 4/19/2024 |
Related Tickers
GILD Gilead Sciences, Inc.
65.42
+0.23%
BMY Bristol-Myers Squibb Company
44.85
+0.34%
MRK Merck & Co., Inc.
131.20
+0.37%
AZN AstraZeneca PLC
75.17
+0.19%
ABBV AbbVie Inc.
159.62
-4.58%
AMGN Amgen Inc.
269.98
+0.22%
LLY Eli Lilly and Company
733.51
+1.19%
PFE Pfizer Inc.
25.40
+0.55%
NVS Novartis AG
97.44
-1.64%
SNY Sanofi
49.13
-0.47%